Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial

Parker Christopher C.; Coleman Robert E.; Sartor Oliver; Vogelzang Nicholas J.; Bottomley David; Heinrich Daniel; Helle Svein I.; OSullivan Joe M.; Fossa Sophie D.; Chodacki Ales; Wiechno Pawel; Logue John; Seke Mihalj; Widmark Anders; Johannessen Dag Clement; Hoskin Peter; James Nicholas D.; Solberg Arne; Syndikus Isabel; Kliment Jan; Wedel Steffen; Boehmer Sibylle; DallOglio Marcos; Franzen Lars; Bruland Oyvind S.; Petrenciuc Oana; Staudacher Karin; Li Rui; Nilsson Sten

首页> 外文期刊>European urology >Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial

【24h】

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial

机译：患有抗阉割前列腺癌患者的镭-223二氯化钠的三年安全性来自第3阶段随机癌症癌症试验中的3阶段随机癌症癌症

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: In Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 versus placebo prolonged overall survival with favorable safety in castration-resistant prostate cancer patients with symptomatic bone metastases. Long-term radium-223 monitoring underlies a comprehensive safety and risk/benefit assessment.

机译：背景：在症状前列腺癌（Alsympca）试验中，在症状中，镭-223与安慰剂延长整体存活率在抗症状骨转移症抗阉割前列腺癌患者中具有良好的安全性。长期镭-223监测下潜综合安全和风险/效益评估。

著录项

来源
《European urology》 |2018年第3期|共9页
作者
Parker Christopher C.; Coleman Robert E.; Sartor Oliver; Vogelzang Nicholas J.; Bottomley David; Heinrich Daniel; Helle Svein I.; OSullivan Joe M.; Fossa Sophie D.; Chodacki Ales; Wiechno Pawel; Logue John; Seke Mihalj; Widmark Anders; Johannessen Dag Clement; Hoskin Peter; James Nicholas D.; Solberg Arne; Syndikus Isabel; Kliment Jan; Wedel Steffen; Boehmer Sibylle; DallOglio Marcos; Franzen Lars; Bruland Oyvind S.; Petrenciuc Oana; Staudacher Karin; Li Rui; Nilsson Sten;
展开▼
作者单位

Royal Marsden NHS Fdn Trust &

Inst Canc Res Sutton Surrey England;

Univ Sheffield Weston Pk Hosp Sheffield S Yorkshire England;

Tulane Canc Ctr New Orleans LA USA;

Comprehens Canc Ctr Nevada Las Vegas NV USA;

St James Univ Hosp Leeds W Yorkshire England;

Akershus Univ Hosp Lorenskog Norway;

Haukeland Hosp Bergen Norway;

Queens Univ Ctr Canc Res &

Cell Biol Belfast Antrim North Ireland;

Radiumhosp Oslo Norway;

Hosp Kochova Chomutov Czech Republic;

Inst Sklodowskiej Curie Ctr Onkol Warsaw Poland;

Christie Hosp Manchester Lancs England;

Centrallasarettet Vaxjo Sweden;

Umea Univ Umea Sweden;

Ullevaal Univ Hosp Oslo Norway;

Mt Vernon Hosp Canc Ctr Northwood Middx England;

Univ Hosp Birmingham NHS Trust Canc Ctr Birmingham W Midlands England;

St Olavs Hosp Trondheim Norway;

Clatterbridge Ctr Oncol Wirral Merseyside England;

Univ Hosp Comenius Univ Jessenius Sch Med Martin Slovakia;

Ruhr Univ Bochum Marien Hosp Herne Dept Urol Herne Germany;

Gemeinschaftspraxis Berlin Germany;

Univ Sao Paulo Hosp Clin Fac Med Inst Canc Estado Sao Paulo Sao Paulo Brazil;

Lanssjukhuset Sundsvall Harnosand Cty Hosp Sundsvall Sweden;

Norwegian Radium Hosp Oslo Oslo Norway;

Bayer HealthCare Pharmaceut Whippany NJ USA;

Bayer AS Oslo Norway;

Bayer HealthCare Pharmaceut Whippany NJ USA;

Karolinska Univ Hosp Stockholm Sweden;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词
ALSYMPCA; Bone metastases; Castration-resistant; prostate cancer; Long-term safety; Radium-223; Follow-up;

机译：Alsympca;骨转移;抵抗力;前列腺癌;长期安全;镭-223;随访;

相似文献

外文文献
中文文献
专利

1. 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的II期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11) [J] . Ji-Yeon Kim, Young-Hyuck Im, Tae-Yong Kim, 癌症（英文版） . 2019,第008期
2. Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial [J] . Parker Christopher C., Coleman Robert E., Sartor Oliver, European urology . 2018,第3期

机译：患有抗阉割前列腺癌患者的镭-223二氯化钠的三年安全性来自第3阶段随机癌症癌症试验中的3阶段随机癌症癌症
3. Re: Effect of Radium-223 Dichloride on Symptomatic Skeletal Events in Patients with Castration-Resistant Prostate Cancer and Bone Metastases: Results from a Phase 3, Double-Blind, Randomised Trial [J] . Taneja Samir S. The Journal of Urology . 2015,第3期

机译：回复：二氯化铀223对去势抵抗性前列腺癌和骨转移患者的症状性骨骼事件的影响：三期，双盲，随机试验的结果
4. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial [J] . SartorO., ColemanR., NilssonS., The lancet oncology . 2014,第7期

机译：223氯化镭对去势抵抗性前列腺癌和骨转移患者症状性骨骼事件的影响：一项三期，双盲，随机试验的结果
5. Castration-Resistant Prostate Cancer: Novel Targets, Agents, and Trials [C] . Evan Y. Yu Genitourinary Cancers Symposium . 2012

机译：抗阉割前列腺癌：新型靶点，药剂和试验
6. Alpha-methylacyl-CoA racemase: A candidate gene for prostate cancer and advanced distal colorectal adenomas in the prostate, lung, colorectal, and ovarian cancer screening trial. [D] . Daugherty, Sarah. 2007

机译：α-甲基酰基辅酶A消旋酶：在前列腺癌，肺癌，结肠直肠癌和卵巢癌筛查试验中，前列腺癌和晚期远端结肠直肠腺瘤的候选基因。
7. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases [O] . Hirotsugu Uemura, Hiroji Uemura, Satsohi Nagamori, -1

机译：对日本有症状的去势抵抗性前列腺癌和骨转移患者进行二氯化镭223二期研究的三年随访
8. Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial [O] . Parker Christopher, Zhan Lin, Cislo Paul, 2017

机译：二氯化镭223（Ra-223）对住院的影响：有症状前列腺癌患者（ALSYMPCA）试验的3期随机Alpharadin分析

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial

摘要

著录项

相似文献

相关主题

期刊订阅